229 related articles for article (PubMed ID: 18710059)
1. [The role of interleukin-6 in rheumatoid arthritis].
Manfredi M; Benucci M
Recenti Prog Med; 2008 Jun; 99(6):291-4. PubMed ID: 18710059
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
Park JY; Pillinger MH
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
Kavanaugh A
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R; Ruderman EM
Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
[TBL] [Abstract][Full Text] [Related]
5. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting interleukin-6 in rheumatoid arthritis.
Choy E
Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 in rheumatoid arthritis.
Nishimoto N
Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
[TBL] [Abstract][Full Text] [Related]
8. [New therapies for rheumatoid arthritis].
Salgado E; Maneiro JR
Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
10. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.
Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Meroni PL; Cugno M
Clin Exp Rheumatol; 2016; 34(3):451-8. PubMed ID: 27086948
[TBL] [Abstract][Full Text] [Related]
11. Biologic agents for rheumatoid arthritis: 2008 and beyond.
Sweiss NJ; Hushaw LL
J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
[TBL] [Abstract][Full Text] [Related]
12. Clinical safety of tocilizumab in rheumatoid arthritis.
Bannwarth B; Richez C
Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy in rheumatoid arthritis.
Köller MD
Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
Furfaro N
J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
[TBL] [Abstract][Full Text] [Related]
16. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
18. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
Matsuno H
Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
[TBL] [Abstract][Full Text] [Related]
19. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 inhibition--tolerability profile and clinical implications.
Strand V; Yazici Y
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
